Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials

Gynecologic Oncology

Volumn 78, Issue 1, 2000, Pages 3-6

  Rose, Peter G ^a   Lappas, Panos T ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HYDROXYUREA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MODEL; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; UTERINE CERVIX CANCER;

EID: 0033938648     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5810     Document Type: Article

References (18)

1. Landis SH, Murray T, Bolden S, Wingo PA: CA Cancer J Clin 49:8-31, 1999
2. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide frequency of eighteen major cancers in 1985. Int J Cancer 54:594-606, 1993
3. SEER Cancer incidence public use data base, 1973-1994, Bethesda, MD, NCI, August 1977
4. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Clarke-Pearson DL, Liao S-Y: A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339-1348, 1999
5. Morris M, Eifel PJ, Lu J, Grisby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM: Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high risk cervical cancer: A randomized Radiation Therapy Oncology Group clinical trial. N Engl J Med 340:1137-1143, 1999
6. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalco S: Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: Results of a randomized Gynecologic Oncology Group study. N Engl J Med 340:1144-1153, 1999
7. Peters WA III, Liu PY, Barrett RJ, Gordon W Jr, Stock R, Berek JF, DiSaia PJ, Souhami L, Grisby P, Alberts DS: Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study. Gynecol Oncol 72:443, 1999
8. Keys HM, Bundy BM, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, Wlaker JL, Gersell D: A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. N Engl J Med 340:1154-1161, 1999
9. NCI Clinical Announcement: Concurrent chemoradiation for cervical cancer. U.S. Department of Public Health, February 1999
10. Elit LM, Gafni A, Levine MN: Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: An Ontario perspective. J Clin Oncol 15:632-639, 1997
11. McGuire W, Neuget AI, Arkian S, Doyle J, Dezii CM: Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 15:640-645, 1997
12. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, LeChevalier T: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 13:2166-2173, 1995
13. NIH Consensus Statement, Cervical Cancer 14:15-16, 1996
14. Drug Topics Red Book. Montvale, NJ, Medical Economics Co., 1998
15. Medicare Resource-Based Relative Value Scale (RBRVS): The Physician's Guide. Chicago, IL, AMA, 1998
16. Internet Address: http://www.hcfa.gov.
17. National Canter for Health Statistics.
18. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD: Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15:369-390, 1995